Cytori Therapeutics Inc. (CYTX) Issues Quarterly Earnings Results
Cytori Therapeutics Inc. (NASDAQ:CYTX) released its earnings results on Wednesday. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.02. Cytori Therapeutics had a negative net margin of 314.07% and a negative return on equity of 175.25%. The business had revenue of $2.61 million for the quarter, compared to the consensus estimate of $2.85 million. During the same quarter in the previous year, the firm earned ($0.60) EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis.
Shares of Cytori Therapeutics (NASDAQ:CYTX) opened at 1.64 on Friday. The firm’s 50-day moving average is $1.88 and its 200 day moving average is $2.32. The company’s market cap is $33.61 million. Cytori Therapeutics has a 1-year low of $1.50 and a 1-year high of $6.15.
An institutional investor recently raised its position in Cytori Therapeutics stock. Perkins Capital Management Inc. increased its stake in shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) by 0.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 389,065 shares of the company’s stock after buying an additional 1,213 shares during the period. Perkins Capital Management Inc. owned 1.90% of Cytori Therapeutics worth $790,000 at the end of the most recent reporting period. 18.89% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have weighed in on CYTX. Maxim Group set a $5.00 target price on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Monday, October 24th. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Monday, August 1st.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Stock Ratings for Cytori Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc. and related stocks with our FREE daily email newsletter.